Your browser doesn't support javascript.
loading
Correlations between plasma markers and brain Aß deposition across the AD continuum: Evidence from SILCODE.
Yu, Xianfeng; Shi, Rong; Zhou, Xia; Zhang, Mingkai; Cai, Yue; Jiang, Jiehui; Han, Ying.
Afiliación
  • Yu X; Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.
  • Shi R; Department of Neurology, the First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Zhou X; School of Information and Communication Engineering, Shanghai University, Shanghai, China.
  • Zhang M; Department of Neurology, the First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Cai Y; Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.
  • Jiang J; Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, China.
  • Han Y; Institute of Biomedical Engineering, School of Life Sciences, Shanghai University, Shanghai, China.
Alzheimers Dement ; 20(9): 6170-6182, 2024 Sep.
Article en En | MEDLINE | ID: mdl-38982860
ABSTRACT

BACKGROUND:

Previous studies have found that Alzheimer's disease (AD)-related plasma markers are associated with amyloid beta (Aß) deposition, but the change of this association in different Aß pathological stages remains unclear.

METHODS:

Data were obtained from the SILCODE. According to the standardized uptake value ratio (SUVR) and Aß stage classification, correlation analysis was performed among plasma biomarkers, and voxel/SUVR values in the regions of interest (ROI) and clinical scale information, respectively. Mediation analysis was used to study the possible pathways.

RESULTS:

The proportion of cognitively normal (CN) and subjective cognitive decline (SCD) was the highest in stages A0 to 1, while in stages A2 to 4, the proportion of mild cognitive impairment (MCI) and AD increased. Plasma phosphorylated tau (p-tau)181 and glial fibrillary acidic protein (GFAP) levels were significantly lower in stage A0 compared to the later phases. Two pathways demonstrated fully mediated effects positron emission tomography (PET) SUVR-plasma p-tau181-Mini-Mental State Examination (MMSE) and PET SUVR-plasma GFAP-MMSE.

DISCUSSION:

This study demonstrated the role of plasma biomarkers in the early stage of AD, especially in SCD, from both the clinical diagnosis and Aß stage dimensions. HIGHLIGHTS Plasma ptau181 and GFAP level serve as indicators of early Alzheimer's disease and the pathologic Aß staging classification. A possible ceiling effect of GFAP was observed in the mid-to-late stages of the AD course. This study confirms the role of AD plasma markers in promoting Aß deposition at an early stage, particularly in females with subjective cognitive decline(SCD). The overlapping brain regions of plasma p-tau181, GFAP, and neurofilament light for Aß deposition in the brain in early AD were distributed across various regions, including the posterior cingulate gyrus, rectus gyrus, and inferior temporal gyrus.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Encéfalo / Biomarcadores / Péptidos beta-Amiloides / Enfermedad de Alzheimer / Disfunción Cognitiva Límite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Alzheimers Dement Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Encéfalo / Biomarcadores / Péptidos beta-Amiloides / Enfermedad de Alzheimer / Disfunción Cognitiva Límite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Alzheimers Dement Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos